about
Sjögren's syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from Short Form 36 questionnaire and a meta-analysisVasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands.Autoantibodies to endothelial cell surface ATP synthase, the endogenous receptor for hsp60, might play a pathogenic role in vasculatides.Efficacy of pastes containing CPP-ACP and CPP-ACFP in patients with Sjögren's syndrome.Immune mediated diseases and immune modulation in the neurocritical care unitMycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trialTranslation and Validation of a Korean Version of the Xerostomia Inventory in Patients with Primary Sjögren's Syndrome.Toxic epitheliopathy from a single application of preservative free oxybuprocaine (0.4%) in a patient with Sjogren's syndrome.Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.Correlation between Tear Osmolarity and Other Ocular Surface Parameters in Primary Sjögren's Syndrome.Metabolic bone disease as a presenting manifestation of primary Sjögren's syndrome: Three cases and review of literature.Primary Sjogren's syndrome and the risk of acute pancreatitis: a nationwide cohort study.New approaches in Sjögren's syndrome therapy.Hypokalemic paralysis as a presenting manifestation of primary Sjögren's syndrome: A report of two casesSjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial.The risk of nontuberculous mycobacterial infection in patients with Sjögren's syndrome: a nationwide, population-based cohort study.Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.Bone Morphogenetic Protein 6 Inhibits the Immunomodulatory Property of BMMSCs via Id1 in Sjögren's Syndrome
P2860
Q30234353-3CDE6883-750E-4858-80C7-BBB266523639Q33428324-B2248D53-AB52-46BF-A5D7-7E1241904FB2Q33822283-C0CC821C-4A08-4B9E-B269-480BF1222FA0Q35575503-02CCBF06-7528-4713-B3BA-34BD3C6BC685Q35729575-40E3463C-DDA4-4408-829A-E418D1B320F0Q36465459-8E0CD4E6-A605-4712-BEF1-68460F74EB9CQ36809655-0FEF77CA-529E-4F80-A507-CDE2962D9167Q37223630-F45775CB-68A9-4486-9E08-E71E757D4C62Q37331753-B4928236-F662-4AE2-B723-42BA03390922Q37667670-E3EA8063-C23A-473D-9A74-D25EDB862FF6Q37949600-6DE199F3-FD79-4633-AD95-6E3FB82C9329Q38628285-3727DC7A-2DB7-4DC7-8696-894EF21AB3CEQ40238844-52B0334E-9443-488C-8050-BDAE7805B408Q41816091-A8CEF7CD-4097-4311-AEBF-B92903CB0D75Q46006385-C15DEF4B-0643-44B6-BFF9-667C1EEF041BQ46846973-FBD8EE72-6326-4CBA-B686-024E940E46B3Q47161206-916DB1AA-6B86-48C6-92D0-90E2A5544EE6Q48341665-C023633C-2BB0-416B-B7D9-F8EAA06C615BQ58803004-2838F47C-B356-4E09-91EA-FAC5E5021AB7
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The management of Sjögren's syndrome.
@ast
The management of Sjögren's syndrome.
@en
type
label
The management of Sjögren's syndrome.
@ast
The management of Sjögren's syndrome.
@en
prefLabel
The management of Sjögren's syndrome.
@ast
The management of Sjögren's syndrome.
@en
P2093
P2860
P356
P1476
The management of Sjögren's syndrome.
@en
P2093
Clio P Mavragani
Haralampos M Moutsopoulos
Niki M Moutsopoulos
P2860
P2888
P304
P356
10.1038/NCPRHEUM0165
P577
2006-05-01T00:00:00Z
P6179
1049679432